Enhanced Compliance Strengthens AI, Digital Transformation Capabilities With New Hire

Enhanced Compliance Inc. (ECI) has appointed Taranjit S. Samra as head of Medical Device Software Engineering, Cybersecurity and AI, reporting to Chief Operating Officer Shital Patel.

“Software, cybersecurity and AI are fundamentally reshaping the future of medical technology,” ECI CEO Brijesh Patel said. “Taranjit brings the strong combination of technical depth, regulatory expertise, and strategic leadership needed to help our clients navigate this evolution with confidence. His appointment significantly strengthens ECI’s ability to support organizations developing the next generation of connected, software-enabled and AI-powered medical technologies.”

Samra has nearly 30 years of experience spanning medical devices, diagnostics, software, digital health, AI, precision medicine, biotechnology, and clinical laboratories. Throughout his career, he has helped healthcare technology companies build quality systems and regulatory frameworks that enable organizations to successfully commercialize emerging technologies while meeting increasingly complex global regulatory requirements.

Samra’s experience includes leading quality and regulatory transformations, implementing enterprise Quality Management Systems (QMS) aligned with U.S. Food and Drug Administration (FDA) QMSR and ISO 13485, supporting FDA Class III PMA approvals, preparing organizations for first-time FDA inspections, and developing modern approaches to software quality, cybersecurity, and AI governance. He has held leadership roles with organizations including Verily (Google Life Sciences), Illumina, Caris Life Sciences, Tempus AI, Guardant Health, Grail, Varian Medical Systems and Sanmina-SCI.

With deep expertise in medical device software and regulatory science, Samra has worked closely with the FDA’s Digital Health initiatives, authored publications on medical device software and global regulatory strategy, and taught graduate-level regulatory science. His work continues to help shape practical, risk-based approaches for AI-enabled quality systems, software engineering, and regulatory compliance.

In his role at ECI, Samra will lead the company’s Medical Device Software Engineering, Cybersecurity and AI practice, partnering with life sciences organizations developing Software as a Medical Device (SaMD), Software in a Medical Device (SiMD), AI-enabled technologies, connected medical devices, and digital health solutions. He will help clients navigate evolving global regulatory expectations while implementing modern software engineering, cybersecurity, quality and AI governance frameworks.

Samra’s appointment further strengthens ECI’s AI & Digital Transformation solution while enhancing the company’s ability to support clients developing software-enabled medical devices, connected products, cybersecurity programs and AI-driven technologies across the entire product lifecycle, executives claim.

“I’m excited to join ECI at such an important time for the life sciences industry,” Samra stated. “Artificial intelligence, software and connected technologies are transforming how medical products are developed, regulated and maintained throughout their lifecycle. ECI’s integrated consulting model uniquely positions us to help organizations successfully navigate this transformation while maintaining the highest standards of quality, compliance and patient safety. I look forward to partnering with our clients as they bring the next generation of healthcare innovation to market.”

Enhanced Compliance Inc. is a global life sciences partner delivering integrated quality, regulatory, and compliance expertise—combined with hands-on engineering execution and advanced packaging and laboratory testing. ECI works alongside medical device, pharmaceutical, biotechnology, and combination product companies across the full product lifecycle—from development and validation through post-market and remediation—helping teams solve complex challenges, strengthen quality systems, and ensure product readiness in highly regulated environments. For more than a decade, ECI has helped life sciences companies solve complex challenges across the product life cycle—enabling them to accelerate timelines, reduce risk, and bring safe, effective products to market with confidence.